Insider Transactions in Q1 2025 at Arvinas, Inc. (ARVN)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 24
2025
|
Angela M Cacace Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,207
-2.09%
|
$67,312
$16.65 P/Share
|
|
Feb 24
2025
|
David K Loomis Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,214
-6.05%
|
$19,424
$16.75 P/Share
|
|
Feb 24
2025
|
John G Houston President and CEO |
SELL
Open market or private sale
|
Direct |
31,338
-1.32%
|
$501,408
$16.65 P/Share
|
|
Feb 24
2025
|
Ian Taylor President, R&D |
SELL
Open market or private sale
|
Direct |
9,020
-2.7%
|
$144,320
$16.65 P/Share
|
|
Feb 13
2025
|
Andrew Saik Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,092
+30.76%
|
-
|
|
Feb 13
2025
|
David K Loomis Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,584
+36.24%
|
-
|
|
Feb 13
2025
|
Angela M Cacace Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,092
+32.72%
|
-
|
|
Feb 13
2025
|
Noah Berkowitz Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,229
+31.76%
|
-
|
|
Feb 13
2025
|
Ian Taylor President, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
20,619
+10.92%
|
-
|
|
Feb 13
2025
|
John G Houston President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
152,000
+11.34%
|
-
|